Dendrite Expands Footprint in Latin America; World's Largest Pharma Companies Use Dendrite Solutions.

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of sales, marketing, compliance and clinical solutions for the life science and pharmaceutical industry, today announced that the company's solutions in Latin America are being utilized by the more than 10,000 sales representatives representing several pharmaceutical companies in the region, including three of the world's largest companies.

Dendrite attributes its growth in the region to a rise in demand for sales force automation and sample management solutions. Dendrite's local market presence, strong pharmaceutical industry-specific knowledge and quality of solutions that offer full capabilities in both Spanish and Portuguese are key factors contributing to the company's growing business operations in the region.

"Our growth in Latin America can be tied directly to the flexibility of our marketing, sales, and compliance solutions to meet the needs of different worldwide markets," said Thierry Durand, vice president Latin America and Global Accounts for Dendrite. "Our presence in Latin America is a reflection of our commitment to offer dependable global reach to our clients."

"Through our customer base in Latin America, Dendrite has built a deeper regional project delivery expertise that not only strengthens our position, but also helps us to cement trusting customer relationships," said Natasha Giordano, senior vice president of Global Accounts for Dendrite.

Dendrite's presence in Latin America includes offices in Argentina, Brazil, Colombia, Mexico, and Venezuela. Dendrite's product and services contracts signed in Latin America include Dendrite's VisiForce (TM) which is designed for emerging life science and pharmaceutical companies, is a complete sales force management system that can be deployed rapidly and is highly scalable and configurable. Other products and services include WebForce(TM) enterprise sales force automation and Pharbase(TM), Dendrite's world-leading master database solution.

About Dendrite

Founded in 1986, Dendrite International, Inc., (NASDAQ: DRTE) provides diversified sales, marketing, clinical and compliance solutions to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.